Skip to contentB
Biolargo, Inc.
B
BLGOBiolargo, Inc. Q3 2023 · 10-Q
Revenue$2.67M$2.67M+78.1% vs Q3 2022 Net Income-$1.51M-$1.51MN/M vs Q3 2022 EPS, diluted—
Gross Profit$1,435,000+90.8% Operating Income-$1,537,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Biolargo, Inc. · CIK 880242 · Engraved from SEC EDGAR
Operating Cash Flowderived-$836,000N/M Margins · derivedGross margin53.7%+3.6 pt vs Q3 2022
Operating margin-57.5%+5.3 pt vs Q3 2022
Net margin-56.4%+0.0 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 14, 2023 · 45 d after period end